Effect of timing and duration of tamsulosin exposure on complications in resident-performed phacoemulsification

Ophthalmic Surg Lasers Imaging. 2011 Sep-Oct;42(5):416-22. doi: 10.3928/15428877-20110602-01. Epub 2011 Jun 9.

Abstract

Background and objectives: Tamsulosin can cause intraoperative floppy iris syndrome and increase the risk of phacoemulsification complications. This study evaluated whether the risk of complications was associated with the timing or duration of preoperative tamsulosin exposure.

Patients and methods: The current study was a retrospective review of electronic medical records of resident-performed phacoemulsification surgeries from 1998 to 2008 at a Veterans Administration Hospital. There were 73 eyes with recent tamsulosin exposure (within 30 days preoperatively) and 28 eyes with remote exposure (> 30 days preoperatively but within 3 years of surgery).

Results: There was a trend toward more total complications in recent compared with remote tamsulosin exposure cases (31.5% vs 14.3%, P = .09). A longer duration of tamsulosin use was not statistically associated with an increased risk of total complications.

Conclusion: The authors were unable to detect a statistically significant effect of duration of tamsulosin use on the risk of intraoperative complications in phacoemulsification surgery.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-1 Receptor Antagonists / administration & dosage
  • Adrenergic alpha-1 Receptor Antagonists / adverse effects*
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Internship and Residency
  • Intraoperative Complications / chemically induced*
  • Iris Diseases / chemically induced*
  • Logistic Models
  • Male
  • Middle Aged
  • Phacoemulsification / adverse effects*
  • Retrospective Studies
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects*
  • Tamsulosin
  • Time Factors

Substances

  • Adrenergic alpha-1 Receptor Antagonists
  • Sulfonamides
  • Tamsulosin

Grants and funding